Download the app
App StorePlay Store
Beige
Login
← All tags

weight loss

Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide in India is expected to get dramatically cheaper, with prices likely to fall by more than half in the coming months. The drop is linked to the entry of smaller brands and a steep decline in raw material costs. A one month dose could fall to as low as ₹500, potentially widening access to the popular weight-loss drug.

Summarised by Beize from a story on The Economic Times on 13 May 2026
Forget 10000 steps New study finds the exact daily number to stop weight regain

Forget 10000 steps New study finds the exact daily number to stop weight regain

A new study challenges the “10,000 steps a day” rule, suggesting you may need far fewer to keep weight from creeping back after dieting. Researchers analyzed thousands of adults and identified roughly 8,500 daily steps as a key threshold for maintaining weight loss. The takeaway: walking isn’t only for shedding pounds, but for protecting progress long term.

Summarised by Beize from a story on The Economic Times on 12 May 2026

Your news, in seconds

App StorePlay Store
Amanda Bynes returns with EDM rap debut Girlfriend and a surprising new brunette makeover

Amanda Bynes returns with EDM rap debut Girlfriend and a surprising new brunette makeover

Amanda Bynes has released her debut EDM-rap track, “Girlfriend,” signaling a major creative pivot after a four-year gap. Alongside the music, she unveiled a new brunette look and a reported 30-pound weight loss, framing the release as part of a personal restart. The project also comes through her partnership with Create Music Group.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly raised its annual profit and revenue outlook after a stronger-than-expected first quarter, powered by steady demand for its GLP-1 therapies. Results followed the company’s initial reporting since launching its oral GLP-1 pill, Foundayo, with continued momentum for weight-loss and diabetes brands Zepbound and Mounjaro.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

A new trial suggests GLP-1 weight-loss drugs such as semaglutide could also curb heavy alcohol use. Researchers report weekly injections halved heavy drinking days among adults with alcohol use disorder. Because the same medicine is already used for obesity, the findings could translate into a new treatment pathway for millions, pending further research.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Type 2 diabetes weight loss may be possible from one procedure trial results

Type 2 diabetes weight loss may be possible from one procedure trial results

A new trial explored whether type 2 diabetes patients could get both improved blood sugar control and weight benefits from a single endoscopic procedure called duodenal mucosal resurfacing. Participants either received the procedure or underwent a sham version, letting researchers compare outcomes while minimizing bias. Results could reshape how doctors approach metabolic control in the future.

Summarised by Beize from a story on The Economic Times on 25 Apr 2026

Never miss a story

App StorePlay Store
Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Weight loss startup Elevate Now lands Rs 18 crore seed funding to upgrade tech and research

Weight loss startup Elevate Now lands Rs 18 crore seed funding to upgrade tech and research

Weight loss platform Elevate Now has raised Rs 18 crore in seed funding, aiming to strengthen its technology and research capabilities. The fresh capital is expected to support product improvements and help the startup develop more effective approaches in the health and weight management space.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Ozempic and Mounjaro demand surges in India as doctors warn of misuse and unsafe marketing

Ozempic and Mounjaro demand surges in India as doctors warn of misuse and unsafe marketing

India’s appetite for weight-loss injectables like Ozempic and Mounjaro is rising fast, with consumers seeking gradual weight reduction. But healthcare professionals are warning that the current regulatory and marketing environment is not keeping pace, increasing the risk of misuse and improper promotion. Calls are growing for stronger oversight to protect patients.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play